Nurix Therapeutics Finalizes Collaboration Agreement With Roche Following Expiration Of Regulatory Waiting Period
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to $2.3 billion.
Nurix made a deal with a big pharmaceutical company called Roche and will get $700 million right now, plus more money later if their medicine works well. When companies get big payments like this, it usually means people think their medicine has a real chance of helping people.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.